A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

• ClinicalTrials.gov Identifier: NCT03978689
• Recruitment Status: Active, not recruiting
• First Posted: June 7, 2019
• Last Update Posted: April 30, 2024
• Sponsor: Cue Biopharma
• Collaborator: Merck Sharp & Dohme LLC
• Information provided by (Responsible Party): Cue Biopharma

Study Description

Brief Summary:

This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition or disease	Intervention/treatment	Phase
Head and Neck Cancer; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV-Related Carcinoma	Drug: CUE-101; Drug: KEYTRUDA®	Phase 1

Detailed Description:

CUE-101 is a novel fusion protein designed to activate and expand a population of tumor specific T cells to eradicate human papilloma virus (HPV)-driven malignancies. HPV causes multiple tumor types including cervical, head and neck squamous cell carcinoma (HNSCC) and anal cancers. Initial testing of CUE-101 will be conducted in HPV16+ HNSCC patients.

The primary objectives of the Part A&B, first-in-human trial, are to assess the safety and tolerability of CUE-101 in subjects with recurrent/metastatic HNSCC in the second line setting and to determine the maximum tolerated dose or recommended Phase 2 dose based on markers of biological activity. Pharmacokinetics (PK), antitumor immune response, preliminary antitumor activity and the potential for immunogenicity will also be assessed. The goal of Part C&D is to characterize the safety, tolerability, and biological effects of CUE-101 in combination with pembrolizumab in patients with recurrent/metastatic HNSCC in the first line setting. This will be an open-label multicenter phase I trial conducted in the U.S. involving approximately 85 patients.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 85 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Phase I dose escalation and expansion
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
• Actual Study Start Date: July 30, 2019
• Estimated Primary Completion Date: November 2024
• Estimated Study Completion Date: May 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: CUE-101 dose escalation and expansion; Part A&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)	Drug: CUE-101; CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A&B and in combination in Parts C&D according to the schedule described in the protocol.
Pembrolizumab and CUE-101; Part C&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)	Drug: CUE-101; CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A&B and in combination in Parts C&D according to the schedule described in the protocol.; Drug: KEYTRUDA®; KEYTRUDA® is first-line therapy in HPV16 and HLA A*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C&D according to the schedule described in the protocol.; Other Name: Pembrolizumab

Outcome Measures

Primary Outcome Measures :

1. Dose Limiting Toxicity [ Time Frame: 36 months ]
   The number of subjects who have dose limiting toxicities (DLTs), defined as clinically significant or ≥ Grade 3 Common Terminology Criteria for Adverse Events (CTCAE) v5.0, changes in adverse events (AEs), safety laboratory tests, physical examinations, electrocardiograms (ECGs), or vital signs
2. Serum PK parameters for CUE-101 [ Time Frame: 36 months ]
   Area under the concentration-time curve (AUC) of CUE-101
3. Serum PK parameters for CUE-101 [ Time Frame: 36 months ]
   Maximum serum concentration (Cmax) of CUE-101
4. Serum PK parameters for CUE-101 [ Time Frame: 36 months ]
   Terminal half-life of CUE-101

Secondary Outcome Measures :

1. Overall response rate (ORR) [ Time Frame: 36 months ]
   For ORR: Complete and partial responses as well as stable disease parameters will be followed

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

General:

1. Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease. Patients must also be willing and able to comply with study procedures, including the acquisition of specified research specimens
2. Age ≥18 years old
3. ECOG performance status of 0 or 1
4. Life expectancy ≥12 weeks
5. Measurable disease as per RECIST 1.1 and documented by CT and/or MRI. Cutaneous or subcutaneous lesions must be measurable by calipers. Note: Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy, or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment
6. R/M HNSCC that has progressed following at least 1 prior systemic therapy. Patients must have received platinum-based chemotherapy and/or pembrolizumab in the first-line setting
7. Patient must have HLA A*0201 genotype as determined by genomic testing performed at a central laboratory designated by the Sponsor.

8. Patient must have histologically and/or cytologically proven tumor(s) that are HPV16+ and express 16INK4A. Archival tissue or FFPE tissue from a biopsy and/or surgery must be available for HPV16 and p16INK4A testing on all patients enrolled. All tumors must test positive for both HPV16 using RNA ISH and p16INK4A expression in tumor cells using IHC analysis determined in a central laboratory designated by the Sponsor. All tumors must have histologically or cytologically confirmed diagnoses.

   Laboratory Features

9. Acceptable laboratory parameters as follows:

   1. Platelet count ≥100 x 103/µL
   2. Hemoglobin ≥9.0 g/dL. Criteria must be met without erythropoietin dependency and without pRBC transfusion within last 2 weeks.
   3. Absolute neutrophil count ≥1.5 × 103/µL in the absence of any growth factor support within 2 wks prior to the initiation of study drug
   4. ALT or AST ≤3.0 × ULN; for patients with hepatic metastases, ALT and AST ≤5 × ULN
   5. Total bilirubin ≤1.5 × ULN, except patients with Gilbert's syndrome, who may enroll if the conjugated bilirubin (total and direct) is within normal limits
   6. Creatinine <1.5 mg/dL, or a calculated or measured creatinine clearance >30 mL/min
   7. Coag: INR or PT ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range of anticoagulants.

   Reproductive Features

10. Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must have a negative serum pregnancy test performed within 72 hours prior to the initiation of study drug administration. Further, female patients of childbearing potential must agree to use acceptable contraceptive measures from the time of main study consent through 30 days after discontinuation of study drug administration. For female patients, 2 forms of contraception must be utilized and may include oral, transdermal, injectable, or implantable contraceptives; intrauterine device; female condom; diaphragm with spermicide; cervical cap; or use of a condom by the sexual partner or a sterile or vasectomized sexual partner. Periodic abstinence (eg, calendar, ovulation, symptothermal, and post ovulation methods) and withdrawal are not considered acceptable forms of contraception in this study.
11. Non-vasectomized male patients with partners of childbearing potential must use barrier contraception. In addition, male patients should also have their partners use another method of contraception from the time of main study consent through 30 days after discontinuation of study drug administration.
12. Female patients should not be pregnant or plan to become pregnant during the course of the trial.
13. Female patients must not be breastfeeding. Previous Checkpoint Inhibitor (CI) Therapy
14. Patients who have previously received an immune CI (eg, anti-PD L1, anti-PD 1, anti-cytotoxic T lymphocyte-associated antigen 4 [CTLA-4]) prior to enrollment must have toxicities related to the CI resolved to ≤Grade 1 or baseline (prior to the CI) to be eligible for enrollment. Note that patients who experienced previous hypothyroidism toxicity on a CI are eligible to enter study regardless of CTCAE grade resolution as long as the patient is well controlled on thyroid replacement hormone.

Exclusion Criteria

1. Patients with symptomatic CNS metastases must have been treated, be asymptomatic, and not have any of the following at the time of enrollment:

   1. Need for concurrent treatment for the CNS disease (eg, surgery, radiation, corticosteroids >10 mg prednisone/day or equivalent);
   2. Progression of CNS metastases on MRI or CT for at least 28 days after last day of prior therapy for the CNS metastases; and/or
   3. Concurrent leptomeningeal disease or cord compression.
2. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
3. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation
4. Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 2 weeks (or 4 weeks, for antibody drugs), prior to the initiation of study drug administration. Patients may be on an investigational or other anti-neoplastic therapy during the screening phase of the study.
5. Treatment with radiation therapy within 2 weeks prior to the initiation of study drug administration.
6. Treatment with corticosteroids (>10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration.

7. History of clinically significant cardiovascular disease including, but not limited to:

   1. Myocardial infarction or unstable angina within the 16 weeks prior to the initiation of study drug
   2. Clinically significant cardiac arrhythmias
   3. Uncontrolled HTN: systolic BP >180 mm Hg, diastolic BP >100 mm Hg
   4. Deep vein thrombosis, pulmonary embolism, stroke, or transient ischemic attack within the 16 weeks prior to the initiation of study drug
   5. QTcB prolongation >480 msec
   6. CHF (NY Heart Association Class III IV)
   7. Pericarditis/clinically significant pericardial effusion
   8. Myocarditis
8. Clinically significant pulmonary compromise (eg, requirement for supplemental oxygen)

9. Clinically significant GI disorders including:

   1. History of GI perforation within 1 year prior to study drug administration. Patients with a history of GI perforation that occurred more than 1 year ago can only be enrolled if the Investigator no longer considers the previously affected area to be at risk for perforation;
   2. History of clinically significant GI bleeding within 3 months prior to the initiation of study drug
   3. History of acute pancreatitis within 3 months prior to the initiation of study drug; and/or
   4. Diverticulitis that is clinically significant in the opinion of the investigator based on the extent or severity of known disease and/or the occurrence of clinically significant disease flares within 4 weeks prior to the initiation of study drug administration.

10. Patients who experienced the following immune checkpoint inhibitor-related AEs are ineligible even if the AE resolved to ≤Grade 1 or baseline:

    1. ≥Grade 3 ocular AE
    2. Changes in liver function tests that met the criteria for Hy's Law (>3 × ULN of either ALT/AST with concurrent >2 × ULN of total bilirubin (total and direct) and without alternate etiology)
    3. ≥Grade 3 neurologic toxicity
    4. ≥Grade 3 colitis
    5. ≥Grade 3 renal toxicity
11. Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than 1 week prior to the initiation of study drug.
12. Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
13. Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction.
14. Second primary invasive malignancy that has not been in remission for >2 years. Exceptions that do not require a 2 year remission include: non-melanoma skin cancer; cervical carcinoma in situ on biopsy; squamous intraepithelial lesion on Pap smear; localized prostate cancer (Gleason score <6); or resected melanoma in situ.
15. History of trauma or major surgery within 4 weeks prior to the initiation of study drug administration.
16. Any serious underlying medical or psychiatric condition that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site.
17. Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for CUE 101.
18. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
19. Dementia or altered mental status that would preclude understanding and rendering of informed consent.
20. Active or history of alcohol or other substance abuse within 1 year prior to the initiation of study drug administration.
21. Any investigative site personnel directly affiliated with this study.
22. Prisoners or other individuals who are involuntarily detained.
23. Any issue that would contraindicate the patient's participation in the study or confound the results of the study.

Parts C and D The patient population to be enrolled will consist of R/M HLA-A*0201-positive adult patients with HPV-driven HNSCC, as confirmed by tumor HPV16 positivity, expression of p16INK4A and tumor expression of PD L1 (CPS ≥1) as determined by an FDA-approved test, eg, the PD L1 IHC 22C3 pharmDx kit approved for use as a companion diagnostic device.

Inclusion Criteria

General:

1. Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease. Patients must also be willing and able to comply with study procedures, including the acquisition of specified research specimens.
2. Age ≥18 years old
3. ECOG performance status of 0 or 1
4. Life expectancy ≥12 weeks

5. Measurable disease as per RECIST 1.1 and documented by CT and/or MRI by the local site investigator/radiology. At least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan. Minimum measurement must be >15 mm in the longest diameter by >10 mm in the short axis. Cutaneous or subcutaneous lesions must be measurable by calipers.

   Note: Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy, or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.

6. All tumors must have histologically or cytologically confirmed diagnoses of recurrent and/or metastatic HNSCC.
7. Patient must have HLA A*0201 genotype as determined by genomic testing performed at a central laboratory designated by the Sponsor prior to enrollment.
8. Patient must have tumor(s) that are HPV16+ and express 16INK4A. Archival tissue or FFPE tissue from a biopsy and/or surgery must be available for HPV16 and p16INK4A testing on all patients enrolled. All tumors must test positive for both HPV16 using RNA ISH and p16INK4A expression in tumor cells using IHC analysis determined in a central laboratory designated by the Sponsor.

9. Patient must have tumor expression of PD L1 (CPS ≥1) as determined by an FDA-approved test.

   Laboratory Features

10. Acceptable laboratory parameters as follows:

    1. Platelet count ≥100 × 103/μL
    2. Hemoglobin ≥9.0 g/dL. Criteria must be met without erythropoietin dependency and without pRBC transfusion within last 2 weeks.
    3. Absolute neutrophil count ≥1.5 × 103/μL in the absence of any growth factor support within 2 weeks prior to the initiation of study drug
    4. ALT or AST ≤2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤5 × ULN
    5. Total bilirubin ≤1.5 × ULN, except patients with Gilbert's syndrome, who may enroll if the conjugated bilirubin (total and direct) is within normal limits
    6. Creatinine ≤1.5 mg/dL, or a calculated or measured creatinine clearance ≥30 mL/min. Creatinine clearance should be calculated as per institutional standard. >1.5 x institutional ULN. Glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance.
    7. Coagulation: INR or PT ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range of anticoagulants.

    Reproductive Features

11. A male participant must agree to use contraception during the treatment period and for at least 120 days following discontinuation of study treatment.

12. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP)
    2. A WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.

Exclusion Criteria

1. Patients who have received prior therapy for R/M disease.

2. Patients with symptomatic CNS metastases must have been treated, be asymptomatic, and not have any of the following at the time of enrollment:

   1. Need for concurrent treatment for the CNS disease (eg, surgery, radiation, corticosteroids >10 mg prednisone/day or equivalent);
   2. Progression of CNS metastases on MRI or CT for at least 28 days after last day of prior therapy for the CNS metastases. If brain imaging is performed to document the stability of existing metastases, MRI should be used if possible. If MRI is medically contraindicated, CT with contrast is an acceptable alternative.
   3. and/or concurrent leptomeningeal disease or cord compression.
3. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
4. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation
5. Treatment with prior systemic anti-cancer therapy including investigational agents within 4 weeks for antibodies or 5 half-lives for other therapies, whichever is shorter, prior to administration of the study drug. Patients may be on an investigational or other anti-neoplastic therapy during the screening phase of the study.
6. Treatment with radiation therapy within 2 weeks prior to the initiation of study drug administration.
7. Treatment with corticosteroids (>10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration.

8. History of clinically significant cardiovascular disease including, but not limited to:

   1. Myocardial infarction or unstable angina within the 16 weeks prior to the initiation of study drug
   2. Clinically significant cardiac arrhythmias
   3. Uncontrolled HTN: systolic BP >180 mm Hg, diastolic BP >100 mm Hg
   4. Deep vein thrombosis, pulmonary embolism, stroke, or transient ischemic attack within the 16 weeks prior to the initiation of study drug
   5. QTcB prolongation >480 msec
   6. CHF (NY Heart Association Class III-IV)
   7. Pericarditis/clinically significant pericardial effusion
   8. Myocarditis
9. Clinically significant pulmonary compromise (eg, requirement for supplemental oxygen)

10. Clinically significant GI disorders including:

    1. History of GI perforation within 1 year prior to study drug administration. Patients with a history of GI perforation that occurred more than 1 year ago can only be enrolled if the Investigator no longer considers the previously affected area to be at risk for perforation;
    2. History of clinically significant GI bleeding within 3 months prior to the initiation of study drug;
    3. History of acute pancreatitis within 3 months prior to the initiation of study drug; and/or
    4. Diverticulitis that is clinically significant in the opinion of the investigator based on the extent or severity of known disease and/or the occurrence of clinically significant disease flares within 4 weeks prior to the initiation of study drug administration.
11. Severe hypersensitivity to pembrolizumab excipients.
12. Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than 1 week prior to the initiation of study drug.
13. Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
14. Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction.
15. Second primary invasive malignancy that has not been in remission for >2 years. Exceptions that do not require a 2 year remission include: non-melanoma skin cancer; cervical carcinoma in situ on biopsy; squamous intraepithelial lesion on Pap smear; localized prostate cancer (Gleason score <6); or resected melanoma in situ.
16. History of trauma or major surgery within 4 weeks prior to the initiation of study drug administration.
17. Any serious underlying medical or psychiatric condition that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site.
18. History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
19. Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for CUE 101.
20. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
21. Dementia or altered mental status that would preclude understanding and rendering of informed consent.
22. Active or history of alcohol or other substance abuse within 3 months prior to the initiation of study drug administration. Medical marijuana use is not allowed on study.
23. Any investigative site personnel directly affiliated with this study.
24. Prisoners or other individuals who are involuntarily detained.
25. Any issue that would contraindicate the patient's participation in the study or confound the results of the study.

Contacts and Locations

Locations

United States, Arizona

University of Arizona

Tucson, Arizona, United States, 85719

United States, California

Stanford University Medical Center

Palo Alto, California, United States, 94305

United States, Connecticut

Yale School of Medicine

New Haven, Connecticut, United States, 06510

United States, District of Columbia

George Washington University Cancer Center

Washington, District of Columbia, United States, 20037

United States, Florida

Moffitt Cancer Center

Tampa, Florida, United States, 33612

United States, Georgia

Emory University School of Medicine

Atlanta, Georgia, United States, 30322

United States, Illinois

Affiliated Oncologists, LLC

Chicago, Illinois, United States, 33612

United States, Maryland

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States, 20231

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

United States, Michigan

University of Michigan

Ann Arbor, Michigan, United States, 48197

Barbara Karmanos Cancer Center/ Wayne State University School of Medicine

Detroit, Michigan, United States, 48201

United States, Missouri

Washington University

Saint Louis, Missouri, United States, 63110

United States, New York

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10017

United States, Ohio

Gabrail Cancer Center

Canton, Ohio, United States, 44718

United States, Tennessee

Vanderbilt-Ingram Cancer Center (VICC)

Nashville, Tennessee, United States, 37232

United States, Texas

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

United States, Washington

University of Washington School of Medicine

Seattle, Washington, United States, 98195

Sponsors and Collaborators

Cue Biopharma

Merck Sharp & Dohme LLC

Investigators

• Study Director: Matteo Levisetti, MD; Cue Biopharma

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Quayle SN, Girgis N, Thapa DR, Merazga Z, Kemp MM, Histed A, Zhao F, Moreta M, Ruthardt P, Hulot S, Nelson A, Kraemer LD, Beal DR, Witt L, Ryabin J, Soriano J, Haydock M, Spaulding E, Ross JF, Kiener PA, Almo S, Chaparro R, Seidel R, Suri A, Cemerski S, Pienta KJ, Simcox ME. CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. Clin Cancer Res. 2020 Apr 15;26(8):1953-1964. doi: 10.1158/1078-0432.CCR-19-3354. Epub 2020 Jan 21.

• Responsible Party: Cue Biopharma
• ClinicalTrials.gov Identifier: NCT03978689
• Other Study ID Numbers: CUE-101-01; MK-3475-A78 ( Other Identifier: Merck Sharp & Dohme LLC ); KEYNOTE-A78 ( Other Identifier: Merck Sharp & Dohme LLC )
• First Posted: June 7, 2019
• Last Update Posted: April 30, 2024
• Last Verified: April 2024

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Cue Biopharma:

KEYNOTE' KN-A78

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell; Head and Neck Neoplasms; Neoplasms by Site; Pembrolizumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action